NeoGenomics, Inc. (BMV:NEO)
Mexico · Delayed Price · Currency is MXN | Market Cap | 44.16B +129.8% |
| Revenue (ttm) | 13.39B +11.2% |
| Net Income | -906.48M |
| EPS | -7.03 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 69.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 400 |
| Open | 300.00 |
| Previous Close | 176.40 |
| Day's Range | 297.00 - 300.00 |
| 52-Week Range | 176.40 - 300.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge... [Read more]
Financial Performance
In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
NeoGenomics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Focused on community oncology, the company leverages a broad portfolio and workflow solutions to drive growth, with NGS revenue expanding at 26% and new products like PanTracer and RaDaR ST strengthening its competitive edge. Strategic investments in R&D, sales, and IT infrastructure support continued margin and cash flow improvements.
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.
NeoGenomics Earnings Call Transcript: Q2 2026
Q2 revenue rose 11% year-over-year to $201.7 million, led by 14% clinical growth and 26% NGS growth. Gross margin expanded 260 bps, and adjusted EBITDA grew 36%. Full-year guidance was raised, with continued focus on high-value testing, margin expansion, and commercial execution.
NeoGenomics Earnings release: Q2 2026
NeoGenomics released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
NeoGenomics Quarterly report: Q2 2026
NeoGenomics has published its Q2 2026 quarterly earnings report on July 28, 2026.
NeoGenomics Slides: Q2 2026
NeoGenomics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
NeoGenomics Reports Second Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has fina...
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes.
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes.
NeoGenomics Transcript: Jefferies Global Healthcare Conference 2026
Q1 saw double-digit revenue growth, driven by clinical and NGS segments, with strategic focus on proprietary product development and margin expansion. Strong ASCO engagement, new product launches, and technology upgrades support sustained growth and improved efficiency.
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will showcase nine scientific abstracts at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).
NeoGenomics Transcript: AGM 2026
The meeting covered board elections, executive compensation, equity plan amendments, and auditor ratification, with a quorum of 89.61% established. Voting results will be published in a Form 8-K, and no questions were raised during the Q&A.
Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares
The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ The base shelf prospectus is accessible, and the prospectus supplement...
Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project
Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights Strategic partnership positions Greenland Mines to lead exploration while Neo reta...
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in t...
NeoGenomics Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth to $186.7M, led by 26% NGS growth and strong clinical demand. Guidance for 2026 was raised, with new product launches and reimbursement wins expected to drive further gains. Adjusted EBITDA rose 27% year-over-year.
NeoGenomics Earnings release: Q1 2026
NeoGenomics released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
NeoGenomics Slides: Q1 2026
NeoGenomics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
NeoGenomics Quarterly report: Q1 2026
NeoGenomics has published its Q1 2026 quarterly earnings report on April 28, 2026.
NeoGenomics Reports First Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.